Kancera AB (publ) (3EE0.F)

0.1260 +0.0018 (+1.45%) At close: 08:03AM CEST

Kancera AB (publ)

Karolinska Institutet Science Park
Nanna Svarts väg 4
Solna 171 65
Sweden
46 8 50 12 60 80
https://www.kancera.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 5

Description

Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.

Corporate governance

Kancera AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.